Anzavir R Tablet

Anzavir R tablet is an antiretroviral drug belonging to the protease inhibitors category, containing the active ingredient Atazanavir, Ritonavir. It is used in the treatment of HIV-1 infection. It is a Human immunodeficiency virus that mainly occurs when a person's immune system is attacked and weakened by the human immunodeficiency virus (HIV). This infection progressively weakens the immune system, making individuals more susceptible to opportunistic infections. This drug is generally not recommended for individuals with hepatic impairment because these medications are primarily metabolized in the liver. Hepatic impairment can affect the liver's ability to properly metabolize drugs, leading to potential accumulation of the medications in the body and an increased risk of adverse effects. Therefore, caution is advised, and alternative treatment options may be considered for individuals with hepatic impairment. The doctor will monitor liver function before and during therapy, especially in patients with underlying hepatic disease, including hepatitis B and hepatitis C, or marked transaminase elevations. Individuals may experience hepatotoxicity when taking this drug. Most patients experience asymptomatic increases in indirect bilirubin, reversible upon discontinuation. Do not reduce the dose. If a concomitant transaminase increase occurs, your doctor will evaluate for alternative etiologies. Do not take this drug if you are allergic to Atazanavir, Ritonavir, and other ingredients. During the early stages of HIV-1 treatment, some patients may experience an inflammatory response to opportunistic infections. This condition is called immune reconstitution syndrome. It can occur after starting the drug or other antiretroviral therapies. Knowing this possibility and monitoring for any signs of worsening infections or inflammatory symptoms is necessary. Inform your healthcare provider if the symptoms concern you or persist longer than usual. PR interval prolongation may occur in some patients. Use caution in patients with preexisting conduction system disease or when administered with other drugs that may prolong the PR interval. Patients with advanced HIV may be at increased risk of elevated triglycerides and pancreatitis (a condition caused by inflammation of the pancreas, a gland behind the stomach). If you have a history of pancreatitis, you may have a greater chance of it returning during treatment with this drug.